ReviewCurrent opinion in biotechnology2012
Engineering commensal bacteria for prophylaxis against infection.
Review in Current opinion in biotechnology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 33 citations in OpenAlex.
- Minimal logic gates for probioticGut microbes · 2025Article
- Surface display of p75, a Lactobacillus rhamnosus GG derived protein, on Bacillus subtilis spores and its antibacterial activity against Listeria monocytogenes.AMB Express · 2020Article
- A platform of genetically engineered bacteria as vehicles for localized delivery of therapeutics: Toward applications for Crohn's disease.Bioengineering & translational medicine · 2018Article
- Development of Cell-Based Sentinels for Nitric Oxide: Ensuring Marker Expression and Unimodality.ACS synthetic biology · 2018Article
- Designer cells programming quorum-sensing interference with microbes.Nature communications · 2018Article
- Quantitative and synthetic biology approaches to combat bacterial pathogens.Current opinion in biomedical engineering · 2017Article
- Sustainable therapies by engineered bacteria.Microbial biotechnology · 2017Article
- Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models.Nature communications · 2017Article
- Targeting of host organelles by pathogenic bacteria: a sophisticated subversion strategy.Nature reviews. Microbiology · 2016Review
- Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes.Diabetes · 2015Article
- Potential of cell-free supernatants from cultures of selected lactic acid bacteria and yeast obtained from local fermented foods as inhibitors of Listeria monocytogenes, Salmonella spp. and Staphylococcus aureus.BMC research notes · 2014Article
- Integrating artificial with natural cells to translate chemical messages that direct E. coli behaviour.Nature communications · 2014Article
- Synthetic promoters functional in Francisella novicida and Escherichia coli.Applied and environmental microbiology · 2014Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Infectious diseases are the leading causes of death worldwide. The development of efficient and low cost prophylactics to prevent pathogenic infection is given high priority in the twenty-first century. Commensal bacteria are largely seen as harmless and can survive symbiotically (in many cases) in niches throughout the human body. Advances in genetic engineering and understanding of pathogenesis have revealed many potential strategies to develop engineered bacteria for prophylaxis purposes: including live vaccines and anti-infective agents. In this review, we discuss recent advances and potentialities of prophylaxis with engineered bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.